NASDAQ · MRKR
Marker Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for MRKR: Nov 12, 2026
Marker Therapeutics, Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.12. The reported EPS for the same quarter last year was $-0.12.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.12 | $-0.07 | $-0.16 | 2 |
| Dec 2026 | $-0.27 | $-0.22 | $-0.32 | 2 |
| Mar 2027 | $-0.22 | $-0.22 | $-0.22 | 1 |
| Jun 2027 | $-0.25 | $-0.25 | $-0.25 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks- RTTNews · Oct 19, 7:59 AM EDTMarker Therapeutics Secures $2.6 Mln FDA Grant To Support Phase 1 Of Pancreatic Cancer Study(RTTNews) – Monday, Marker Therapeutics, Inc. (MRKR) announced that it has been awarded $2.6 million from the U.S. Food and Drug Administration to support a Phase 1 clinical study evaluating its lead investigational MAR-T cell therapy, MT-601, in patients with locally advanced un
- Zacks · Oct 16, 11:00 AM EDTAll You Need to Know About MARKER THERAPEUTICS (MRKR) Rating Upgrade to Strong BuyMARKER THERAPEUTICS (MRKR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- Zacks · Oct 16, 3:04 AM EDTNew Strong Buy Stocks for October 16thUGP, SCSC, MRKR, SLGL and MEOH have been added to the Zacks Rank #1 (Strong Buy) List on October 16, 2026.
- RTTNews · Sep 22, 12:45 PM EDTMarker Highlights Expanded Manufacturing Support For MT-601(RTTNews) – Marker Therapeutics, Inc. (MRKR), announced on Tuesday that its lead program MT-601 (neldaleucel) will benefit from expanded manufacturing capabilities following the formation of Kincellis Advanced Therapies, a U.S. cell therapy contract development and manufacturing
- Zacks · Aug 6, 9:50 AM EDTAurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings EstimatesAurinia (AUPH) delivered earnings and revenue surprises of +47.37% and -0.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jun 26, 4:59 AM EDTZacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and MarkerIndivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.
- Zacks · Jun 25, 8:40 AM EDT5 Small Drug Stocks to Invest in Amid a Biotech ComebackInnovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.
- Zacks · May 20, 12:00 PM EDTMARKER THERAPEUTICS (MRKR) Upgraded to Buy: What Does It Mean for the Stock?MARKER THERAPEUTICS (MRKR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks · May 15, 12:55 PM EDTProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue EstimatesPROKIDNEY CP (PROK) delivered earnings and revenue surprises of -7.69% and +222.86%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · May 14, 5:50 PM EDTBioStem Technologies, Inc. (BSEM) Reports Q1 Loss, Tops Revenue EstimatesBioStem Technologies, Inc. (BSEM) delivered earnings and revenue surprises of -85.71% and +7.64%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Mar 18, 6:45 PM EDTMARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue EstimatesMARKER THERAPEUTICS (MRKR) delivered earnings and revenue surprises of +80.49% and +83.83%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Mar 5, 5:20 PM ESTProfound Medical (PROF) Reports Q4 Loss, Misses Revenue EstimatesProfound Medical (PROF) delivered earnings and revenue surprises of 0.00% and -21.87%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Marker Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.